To address the translation potential of the model, it will be essential to expand the dataset of drug exposure and to collect data from patient follow-up, including the detection and quantification of KRAS mutations on tumour recurrences (locally or in metastatic disease), and clinical outcome. Here, KRAS is linked to metastatic neoplasm.